DNA-Guided Precision Medicine for Cancer: A Case of Irrational Exuberance?

Precision treatment with targeted cancer drugs requires the selection of patients who are most likely to benefit from a given therapy. We argue here that the use of a combination of both DNA and transcriptome analyses will significantly improve drug response prediction.

Saved in:
Bibliographic Details
Published inCancer discovery Vol. 6; no. 2; pp. 130 - 132
Main Authors Voest, Emile E, Bernards, Rene
Format Journal Article
LanguageEnglish
Published United States 01.02.2016
Subjects
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Humans
Molecular Targeted Therapy
Mutation
Neoplasms - drug therapy
Neoplasms - genetics
Patient Selection
Precision Medicine
Sequence Analysis, DNA
Sequence Analysis, RNA
Treatment Outcome
Online AccessGet full text

Cover

More Information
Summary:Precision treatment with targeted cancer drugs requires the selection of patients who are most likely to benefit from a given therapy. We argue here that the use of a combination of both DNA and transcriptome analyses will significantly improve drug response prediction.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2159-8274
2159-8290
DOI:10.1158/2159-8290.CD-15-1321